Jack Allen
Stock Analyst at Robert W. Baird
(0.04)
# 4,404
Out of 4,423 analysts
330
Total ratings
30.2%
Success rate
-16.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LYEL Lyell Immunopharma | Initiated Coverage: Buy | $49 | $12.74 | +284.62% | 1 | May 1, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Hold | $7 → $13 | $15.67 | -17.04% | 25 | Apr 27, 2026 | |
| ALLO Allogene Therapeutics | Maintained: Buy | $7 → $9 | $2.00 | +350.00% | 23 | Apr 14, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $47 → $40 | $27.44 | +45.77% | 12 | Feb 13, 2026 | |
| TIL Instil Bio | Downgraded: Hold | $180 → $7 | $7.50 | -6.67% | 28 | Jan 7, 2026 | |
| MREO Mereo BioPharma Group | Maintained: Buy | $8 → $1 | $0.3094 | +223.21% | 5 | Dec 29, 2025 | |
| VOR Vor Biopharma | Maintained: Buy | $64 → $46 | $14.49 | +217.46% | 29 | Dec 23, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintained: Hold | $52 → $44 | $54.09 | -18.65% | 13 | Nov 11, 2025 | |
| TSHA Taysha Gene Therapies | Maintained: Buy | $7 → $12 | $6.42 | +86.92% | 26 | Oct 2, 2025 | |
| LCTX Lineage Cell Therapeutics | Reiterated: Buy | $5 | $1.21 | +313.22% | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $6 | $2.69 | +123.05% | 9 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.72 | +383.87% | 27 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 → $4 | $2.09 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.019 | n/a | 14 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $12.14 | n/a | 17 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $84 | $28.60 | n/a | 9 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $2.98 | n/a | 26 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $72 → $65 | $54.69 | n/a | 9 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $27 | $11.90 | n/a | 17 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $200 → $25 | $12.99 | n/a | 9 | Sep 26, 2023 |
Lyell Immunopharma
May 1, 2026
Initiated Coverage: Buy
Price Target: $49
Current: $12.74
Upside: +284.62%
Intellia Therapeutics
Apr 27, 2026
Maintained: Hold
Price Target: $7 → $13
Current: $15.67
Upside: -17.04%
Allogene Therapeutics
Apr 14, 2026
Maintained: Buy
Price Target: $7 → $9
Current: $2.00
Upside: +350.00%
Ultragenyx Pharmaceutical
Feb 13, 2026
Maintained: Buy
Price Target: $47 → $40
Current: $27.44
Upside: +45.77%
Instil Bio
Jan 7, 2026
Downgraded: Hold
Price Target: $180 → $7
Current: $7.50
Upside: -6.67%
Mereo BioPharma Group
Dec 29, 2025
Maintained: Buy
Price Target: $8 → $1
Current: $0.3094
Upside: +223.21%
Vor Biopharma
Dec 23, 2025
Maintained: Buy
Price Target: $64 → $46
Current: $14.49
Upside: +217.46%
CRISPR Therapeutics AG
Nov 11, 2025
Maintained: Hold
Price Target: $52 → $44
Current: $54.09
Upside: -18.65%
Taysha Gene Therapies
Oct 2, 2025
Maintained: Buy
Price Target: $7 → $12
Current: $6.42
Upside: +86.92%
Lineage Cell Therapeutics
Sep 23, 2025
Reiterated: Buy
Price Target: $5
Current: $1.21
Upside: +313.22%
Aug 13, 2025
Maintained: Buy
Price Target: $10 → $6
Current: $2.69
Upside: +123.05%
Jul 17, 2025
Reiterated: Buy
Price Target: $18
Current: $3.72
Upside: +383.87%
May 14, 2025
Maintained: Hold
Price Target: $5 → $4
Current: $2.09
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $0.019
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $12.14
Upside: n/a
Nov 6, 2024
Maintained: Buy
Price Target: $84
Current: $28.60
Upside: n/a
Nov 5, 2024
Maintained: Buy
Price Target: $10
Current: $2.98
Upside: n/a
Oct 30, 2024
Maintained: Hold
Price Target: $72 → $65
Current: $54.69
Upside: n/a
Nov 16, 2023
Maintained: Hold
Price Target: $27
Current: $11.90
Upside: n/a
Sep 26, 2023
Downgraded: Hold
Price Target: $200 → $25
Current: $12.99
Upside: n/a